Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Anji Pharma Closes $70 Million Series B for US-China Drug In-licensing

publication date: Sep 28, 2021

Anji Pharma, a Cambridge, MA-Shanghai in-licensing company, closed a $70 million Series B financing to seed its oncology pipeline and continue global trials of its two metabolic assets. CR Capital, the VC arm of China Resources, was the only investor in the round. Anji conducts joint US-China clinical trials of its candidates. The company uses a "dynamic equity" approach to its joint venture partnerships, aiming to make smaller upfront payments for the candidates, and then earning additional equity for milestones and sharing development responsibility with the originator company. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital